Is Apyx Medical Corporation (APYX) a Buy, Sell, or Hold?
Apyx Medical Corporation
NASDAQ:APYX
$4.22 USD
-$0.04 (-0.94%)
- Volume
- 61.81K
- Average Volume
- 174.48K
- Market Capitalization
- $176.87M
- P/E Ratio
- -18.96
- Dividend Yield
- 0.00%
- Price Target
- $6.50
- Year High
- $5.08
- Year Low
- $1.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.80
| Source | Headline |
|---|---|
|
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), will return to Miami Swim Week with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations. prnewswire.com - 2026-05-27 09:51:00 |
|
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach globenewswire.com - 2026-05-21 08:00:00 |
|
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open 1. globenewswire.com - 2026-05-14 08:00:00 |
|
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON globenewswire.com - 2026-05-11 08:00:00 |
|
Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript
Apyx Medical Corporation (APYX) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-07 19:11:17 |
|
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
Apyx Medical (APYX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.1 per share a year ago. zacks.com - 2026-05-07 09:51:05 |
|
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026. globenewswire.com - 2026-05-07 07:00:00 |
|
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th. globenewswire.com - 2026-04-23 08:00:00 |
